Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.

Heidenreich A, Witjes WP, Bjerklund-Johansen TE, Patel A; EAU Research Foundation.

Urol Int. 2012;89(1):30-8. doi: 10.1159/000338810. Epub 2012 Jun 13.

PMID:
22699678
2.

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C.

Clin Genitourin Cancer. 2006 Mar;4(4):257-62. Review.

PMID:
16729908
3.

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.

Sternberg CN, Baskin-Bey ES, Watson M, Worsfold A, Rider A, Tombal B.

BMC Urol. 2013 Nov 9;13:58. doi: 10.1186/1471-2490-13-58.

4.

Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.

Surcel CI, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, Ploussard G, van den Bergh RC, van Oort IM, Yossepowitch O, Sedelaar JP, Giannarini G; Members of Prostate Cancer Working Group of Young Academic Urologists Working Party; Members of Young Urologists Office of European Association of Urology.

BJU Int. 2015 Apr;115(4):571-9. doi: 10.1111/bju.12796. Epub 2014 Aug 11.

5.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
6.

[Systemic treatment of metastatic prostate cancer].

Wörmann B, Wolff JM.

Urologe A. 2010 Feb;49(2):221-7. doi: 10.1007/s00120-010-2238-3. Review. German.

PMID:
20180063
7.

Preservation of bone health in prostate cancer.

Lattouf JB, Saad F.

Curr Opin Support Palliat Care. 2007 Oct;1(3):192-7. doi: 10.1097/SPC.0b013e3282f0c74f. Review.

PMID:
18685362
8.

Bisphosphonates for cancer patients: why, how, and when?

Body JJ, Mancini I.

Support Care Cancer. 2002 Jul;10(5):399-407. Epub 2001 Oct 19. Review.

PMID:
12136223
9.

Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.

Saad F, Colombel M.

Expert Rev Anticancer Ther. 2010 Dec;10(12):1991-2002. doi: 10.1586/era.10.191. Review.

PMID:
21110764
10.
11.

Bone health management in men undergoing ADT: examining enablers and barriers to care.

Damji AN, Bies K, Alibhai SM, Jones JM.

Osteoporos Int. 2015 Mar;26(3):951-9. doi: 10.1007/s00198-014-2997-6. Epub 2014 Dec 20.

PMID:
25526712
12.

Trends in the use of androgen deprivation in prostate cancer.

Salminen EK, Wickström JE, Vahlberg T, Duchesne GM.

Acta Oncol. 2004;43(4):382-7.

PMID:
15303500
14.

Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers.

Jensen BT, Dielenseger P, Drudge-Coates L, Flynn K, Hieronymi S, Erik van Muilekom HA, Pieters R, Voss LB.

Eur J Oncol Nurs. 2012 Feb;16(1):42-53. doi: 10.1016/j.ejon.2011.02.006. Epub 2011 Mar 22.

15.

Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.

Saad F, Sternberg CN.

Nat Clin Pract Urol. 2007 Feb;4 Suppl 1:S3-13. Review.

PMID:
17264863
16.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.

PMID:
17404365
17.

Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.

van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW.

BJU Int. 2012 Jul;110(2):180-7. doi: 10.1111/j.1464-410X.2011.10679.x. Epub 2011 Nov 23.

18.

5A prospective survey of current prostate biopsy practices among oncological urologists.

Brewster S, Turkeri L, Brausi M, Ravery V, Djavan B.

Can J Urol. 2010 Apr;17(2):5071-6.

PMID:
20398444
19.

Maintaining bone health in prostate cancer throughout the disease continuum.

Saad F, Eastham J.

Semin Oncol. 2010 Jun;37 Suppl 1:S30-7. doi: 10.1053/j.seminoncol.2010.06.007. Review.

PMID:
20682370
20.

[Treatment of prostate cancer].

Romics I.

Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810. Hungarian. No abstract available.

PMID:
20332076

Supplemental Content

Support Center